

Novel Monoclonal Antibodies for the Treatment of Alzheimers Disease using KISUNLA Drug

Vaishnavi Pravin Titare¹, Mrs. Sneha K. Salve², Dr. M. D. Kitukale³

Student, Department of Pharmacology¹

Assistant Professor and Guide M. Pharm²

Principal, M. Pharm, Ph.D³

Pataldhamal Wadhawani College of Pharmacy Yavatmal, Maharashtra, India

Abstract: For persons with early-stage symptomatic Alzheimer's disease (AD), including those with mild cognitive impairment and mild cognitive dementia stages of the disease with confirmed amyloid pathology, KISUNLA (donanemab-azbt) is a disease-modifying treatment. Nearly half of research participants finished their course of treatment with Kisunla within a year, making it the first and only amyloid plaque targeting medication that uses a limited duration treatment regimen based on amyloid plaque elimination. For those with early-stage symptomatic Alzheimer's disease who desperately require an efficient therapeutic alternative, Kisunla shows extremely significant results.

Keywords: Alzheimers Disease, dementia, monoclonal antibodies, Neurodegenerative disease